Otonomy, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$11.6M
Doctors Paid
395
Transactions
1,758
2021 Total
$123,263
Payment Breakdown by Category
Research$10.7M (92.9%)
Consulting$477,801 (4.1%)
Food & Beverage$13,314 (0.1%)
Royalty/License$12,987 (0.1%)
Travel$10,882 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10.7M | 1,008 | 92.9% |
| Consulting Fee | $477,801 | 117 | 4.1% |
| Grant | $200,671 | 3 | 1.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $105,527 | 61 | 0.9% |
| Food and Beverage | $13,314 | 420 | 0.1% |
| Royalty or License | $12,987 | 17 | 0.1% |
| Travel and Lodging | $10,882 | 25 | 0.1% |
| Education | $1,919 | 106 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $1,500 | 1 | 0.0% |
Payments by Type
Research
$10.7M
1,008 transactions
General
$824,601
750 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease | $6.0M | 11 | 178 |
| A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-313 Given as a Single Intratympanic Injection in Subjects With Subjective Tinnitus | $2.3M | 1 | 110 |
| STUDY OF OTO-104 IN SUBJECTS WITH UNILATERAL MENIERE'S DISEASE | $842,639 | 2 | 283 |
| A 6-MONTH EXTENSION STUDY OF OTO-104 IN MENIERE'S DISEASE | $538,440 | 1 | 238 |
| A randomized, Double-Blind, Placebo-Controlled Phase 1/2 study of OTO-413 given as a single intratymoanic injection in subjects with speech-in-noise hearing impairment | $351,801 | 0 | 23 |
| STUDY OF OTO-104 IN SUBJECTS AT RISK FROM CISPLATIN-INDUCED HEARING LOSS | $318,156 | 10 | 62 |
| PHASE 3 STUDY OF OTO-201 IN ACUTE OTITIS EXTERNA | $175,057 | 4 | 70 |
| A randomized, Double-Blind, Placebo-Controlled Phase 1/2 study of OTO-413 given as a single Intratympanic injection in subjects with speech-in-noise hearing impairment | $119,163 | 0 | 11 |
| OPEN-LABEL STUDY OF OTO-201 IN PEDIATRIC SUBJECTS WITH A HISTORY OF OTITIS MEDIA REQUIRING TYMPANOSTOMY TUBES | $71,042 | 1 | 22 |
| A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-413 Given as a Single Intratympanic Injection in Subjects With Speech-in-noise Hearing Impairment | $15,492 | 0 | 1 |
| A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease | $10,500 | 0 | 4 |
| A prospective, randomized, double blind, placebo-controlled, multicenter, Phase 3 efficacy and safetystudy of OTO-104 given as a single intratympanic injection in subjects with unilateral Meniere's disease. | $5,450 | 0 | 2 |
| A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease | $4,004 | 0 | 1 |
| An 8-Week, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Administration in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes | $1,138 | 0 | 1 |
| A 6-MONTH EXTENSION STUDY OF OTO-104 IN MENIERES DISEASE | $80.00 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 16
| Doctor | Specialty | Location | Total | 2017 |
|---|---|---|---|---|
| Dr. Roy Lewis, Md, MD | Otolaryngology | Mooresville, NC | $11.54 | $0 |
| Mr. Paul Dibiase, Md, MD | Plastic Surgery within the Head & Neck | Steubenville, OH | $11.24 | $0 |
| Darby Marshall, Md, MD | Otolaryngology | Scottsboro, AL | $11.22 | $0 |
| Kenneth Walker, Md, MD | Otolaryngology | Warner Robins, GA | $11.19 | $0 |
| Nila Novotny, M.d, M.D | Otolaryngology | Columbus, NE | $11.14 | $0 |
| James Massey, M.d, M.D | Otolaryngology | Scottsbluff, NE | $11.11 | $0 |
| Dr. Paul Conrad, Md Facs, MD FACS | Otolaryngology | Quincy, IL | $11.09 | $0 |
| Dr. Joseph Creely, Md, MD | Otolaryngology | Louisville, KY | $11.07 | $0 |
| Bruce Morgan, Md, MD | Family Medicine | Birmingham, AL | $10.96 | $0 |
| Dr. Katherine Aberle, Md, MD | Otolaryngology | Merriam, KS | $10.86 | $0 |
| Dr. David Heichel, M.d, M.D | Otolaryngology | Marquette, MI | $10.83 | $0 |
| Matthew Dahl, Md, MD | Otolaryngology | Salt Lake City, UT | $10.80 | $0 |
| John Bennett, Md, MD | Otolaryngology | Salt Lake City, UT | $10.80 | $0 |
| Mr. Steven Miller, M.d, M.D | Otolaryngology | Salt Lake City, UT | $10.80 | $0 |
| Christina Gillespie, M.d, M.D | Otolaryngology | Toms River, NJ | $10.78 | $0 |
| Atul Balwally, Md, MD | Otolaryngology | Dayton, OH | $10.74 | $0 |
| Dr. Janaki Emani, M.d, M.D | Otolaryngology | Lugoff, SC | $10.72 | $0 |
| James Lowery, Md, MD | Otolaryngology/Facial Plastic Surgery | Columbus, OH | $10.70 | $0 |
| Michael Johnson, M.d, M.D | Otolaryngology | Saint Paul, MN | $10.55 | $0 |
| Dr. Phillip Chaffin, Md, MD | Pediatric Otolaryngology | Provo, UT | $10.40 | $0 |
About Otonomy, Inc.
Otonomy, Inc. has made $11.6M in payments to 395 healthcare providers, recorded across 1,758 transactions in the CMS Open Payments database. In 2021, the company paid $123,263. The top product by payment volume is OTO-313 ($513,049).
Payments were distributed across 27 medical specialties. The top specialty by payment amount is Internal Medicine ($339,126 to 5 doctors).
Payment categories include: Food & Beverage ($13,314), Consulting ($477,801), Research ($10.7M), Travel & Lodging ($10,882), Royalties ($12,987).
Otonomy, Inc. is associated with 4 products in the CMS Open Payments database, including OTO-313, OTO-413, and OTO-104.